NuVasive (NuVasive) Interest Expense : $-19 Mil (TTM As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NuVasive Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NuVasive's interest expense for the three months ended in Jun. 2023 was $ -6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NuVasive's Operating Income for the three months ended in Jun. 2023 was $ 28 Mil. NuVasive's Interest Expense for the three months ended in Jun. 2023 was $ -6 Mil. NuVasive's Interest Coverage for the quarter that ended in Jun. 2023 was 4.62. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NuVasive Interest Expense Historical Data

The historical data trend for NuVasive's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Interest Expense Chart

NuVasive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-37.86

-38.53

-70.47

-21.06

-17.42

NuVasive Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Expense	Get a 7-Day Free Trial															-4.35	-4.35	-4.34	-4.38	-6.01

NuVasive Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19 Mil.

NuVasive (NAS:NUVA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NuVasive's Interest Expense for the three months ended in Jun. 2023 was $-6 Mil. Its Operating Income for the three months ended in Jun. 2023 was $28 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was $545 Mil.

NuVasive's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2023 )	/	Interest Expense (Q: Jun. 2023 )
	=	-1	*	27.777	/	-6.008
	=	4.62

The higher the ratio, the stronger the company's financial strength is.

NuVasive (NuVasive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

12101 Airport Way, Broomfield, CO, USA, 92121

Website

https://www.nuvasive.com

NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.

Executives

Michael Farrington	officer: SVP, People and Culture	7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry	director, officer: Chief Executive Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton	officer: SVP, CHRO	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo	director	ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale	officer: Chief Human Resources Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore	officer: EVP, Global Business Units	7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher	officer: EVP, Global Commercial	14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link	officer: Exec. VP U.S. Sales	7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh	officer: EVP and CFO	675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf	officer: SVP, Global Operations	7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock	officer: President, U.S. Commercial	7475 LUSK BLVD, SAN DIEGO CA 92121